A disproportionality analysis of CDK4/6 inhibitors in the FDA Adverse Event Reporting System (FAERS)
Authors:
Open Access
- 5 August 2024
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 24 (1) , 25-33
Abstract
The FDA Adverse Event Reporting System (FAERS) was used to mine and evaluate adverse events (AEs) associated with cyclin-dependent kinase (CDK) 4/6 inhibitors, thereby providing a reference for clinical rational drug use. AE data related to CDK4/6 inhibitors from the first quarter of 2015 to the first quarter of 2023 were acquired from FAERS while the signal mining was processed using the reporting odds ratio (ROR) method and Bayesian confidence propagation neural network (BCPNN) method. The number of AE reports for CDK4/6 inhibitors was respectively 132,494 for palbociclib 56,151 for ribociclib, and 7,014 for abemaciclib. The corresponding numbers of AE signals were 319, 517, and 59, with the number of involved System Organ Class (SOC) being 23, 23, and 15, mainly involving blood and lymphatic system disorders, respiratory, thoracic and mediastinal disorders, hepatobiliary disorders, skin and subcutaneous tissue disorders, etc. CDK4/6 inhibitors could lead to pulmonary toxicity, myelosuppression, skin reactions, etc. Special attention should be paid to abemaciclib for interstitial lung disease (ILD), erythema multiforme, and thrombosis risk; ribociclib for cardiac toxicity, hepatotoxicity, and musculoskeletal toxicity; palbociclib for neurocognitive impairment and osteonecrosis of the jaw.Keywords
Funding Information
- the Chengdu Municipal Health Commission 2022 Chengdu Medical Research Topic (Nos. 2022349)
- the Research Project of the Science and Technology Development Program of Affiliated Hospital of North Sichuan Medical College (2022JC027)
This publication has 44 references indexed in Scilit:
- Association between CDK4/6 inhibitors and drug‐related osteonecrosis of the jaw: A pharmacoepidemiological study using the FDA Adverse Events Reporting SystemInternational Journal of Cancer, 2024
- A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of two real-world databasesInternational Journal of Clinical Pharmacy, 2024
- Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting SystemAmerican Journal of Clinical Dermatology, 2021
- How selective are clinical CDK4/6 inhibitors?Medicinal Research Reviews, 2020
- Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessmentBreast Cancer Research and Treatment, 2020
- Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3The Oncologist, 2020
- Serum concentration of the CKD4/6 inhibitor abemaciclib, but not of creatinine, strongly predicts hematological adverse events in patients with breast cancer: a preliminary reportInvestigational New Drugs, 2020
- The Role of CDK4/6 Inhibitors in Breast CancerCurrent Treatment Options in Oncology, 2019
- A Model to predict severity of drug‐induced liver injury in humansHepatology, 2016
- Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancerCancer Chemotherapy and Pharmacology, 2016